The Human Variable 

The Physics of Survival reframes human stability as the core infrastructure of civilization. This white paper introduces Terrain Intelligence—a unifying systems framework that links space medicine, chronic illness, and climate resilience under one predictive model. Drawing on NASA Human Research Program findings and longitudinal public-health data, Cynthia Adinig demonstrates that physiological collapse in microgravity mirrors the same autonomic and immune failure seen in Lon

FEMA’s flood plans overlook infection-associated chronic conditions now affecting one-quarter of U.S. adults. This CYNAERA white paper introduces biologic disaster modeling using US-CCUC™, ESA™, VitalGuard™, and MoldX™ to forecast medical surges from mold, heat, and power loss. Applying these systems could prevent 70 percent of non-trauma ER visits and save $7.4 billion annually in federal costs.

Here I apply CYNAERA’s analytical framework to the unlikely case of a consumer snack, Frito-Lay’s Baked Lay’s, as an emergent functional-nutrition platform for dysautonomia and MCAS patients. Using CYNAERA’s prevalence modeling (US-CCUC™, S³™, Pathos™, SymCas™, BRAGS™) and global market-behavior analytics, I examine how a legacy brand could reposition a common product into a precision-nutrition solution. A $3 billion opportunity in plain sight.

Traditional medicine isolates diagnoses by organ or specialty. CYNAERA’s terrain logic views the body as an interdependent system where immune, endocrine, and autonomic signals co-determine stability. The Playbook applies three key insights from the Primary Chronic Trigger (PCT) Blueprint. Chronic illness begins with temporal ignition, an event that tips an unstable terrain. Chronicity persists when recovery conditions (RC) remain incomplete.

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

Infection-associated chronic conditions (IACCs) describe a single clinical terrain that appears under many labels—Long COVID, ME/CFS, POTS, MCAS, hEDS overlap, and post-infectious states following EBV, H1N1, Lyme, and Ebola. Triggers differ; downstream biology converges. Across cohorts, patients show immune dysregulation, autonomic instability, mitochondrial hypometabolism, mast-cell mediator sensitivity, connective-tissue fragility, and chronic neuroinflammation.